ReMonit RCT 240+ axSPA pts Remote Monitoring & Patient-initiated Care NON INFERIOR Usual care for ASDAS <2.1 over 18mo No diff between Patient-initiated Care & Remote Monitoring No diff in disease activity & function >90% satisfaction in all arms #EULAR2024 @RheumNow LB0004 https://t.co/mLTS5fLXFN

Scleroderma: the present, and the future. #EULAR2024 @RheumNow https://t.co/v5vxfmM4i3

Open-label extension of BE MOBILE 2 Ph3 Bimekizumab in r-axSpA 200 pts w/ 2yr radiographic outcome 85.3% non progressors (mSASSS CfB ≤0.5) 92.1% (mSASSS CfB <2) 83.1% had existing structural damage (mSASSS ≥2) at BL #EULAR2024 @RheumNow Abst LBA0003 https://t.co/DQeiXHDnSF

PRO-SPIRIT 1100+ PsA Observational study IXE i= TNFi and JAKi for improving joint dis activity in IXE higher previous b/tsDMARD & less concomitant csDMARDs IXE & IL-17Ai = faster improvement cDAPSA than IL-12/23i or IL-23i Abst LBA0002 #EULAR2024 @RheumNow https://t.co/8DbtCQECNN

IL-6 Immunotherapy for knee OA PPV-06 FTIH Phase 1 Is it safe? looks it, no serious AES, 6mo follow up Is it immunogenic? apparently so, IL-6 Ab & neutralizing Ab Does it work? will have to wait for Phase 2 Somehow bold knowing TCZ did not work in hand OA AbstLBA0011 #EULAR2024… https://t.co/pO0Dx3jl8E https://t.co/p1zYUtgFoM

#Scleroderma updated #EULAR2024 #recommendations @eular_org SKIN Are they good enough? Great work by task force @EUSTAR_org Do we alter initial Rx if v high mRSS? Ex #MMF not much improvement on skin vs #RTX #Cyclo Or combo Rx? We need to improve #SoC ?CAR-T ? RCT @RheumNow https://t.co/WhEzDdjVeu

#Scleroderma updated #EULAR2024 #recommendations @eular_org Are they good enough? Great work by task force @EUSTAR_org #PAH my thoughts Where does #sotaracept in #PAH fit in Not mentioned ?#selexipag before #epoprostenol For sure there is country variant @RheumNow https://t.co/3dJ6eusSkU

#EULAR2024 LBA0001 New Steroid-sparring therapy for #GCA. Phase 3 RCT showed Upadacitinib 15mg met primary endpoint (sustained clin remission frm Wks 12-52 & adherence to 26Wk GC taper) vs PBO [46% vs 29%] & multiple secondary endpoints. No new safety signals @RheumNow https://t.co/edfSZkMuy2

#EULAR2024 POS0417 Using EXPLORE Inflammation I & II proteomics, marked immune dysregulation was seen in new ANA+ referral vs HC. 34% progressed to #lupus & #Sjogren. Six potential baseline biomarkers identified & closely resembled established SLE. Validation is ongoing @RheumNow https://t.co/I6HygqNwf7

Nipocalimab (anti-FcRn - i.e. PLEX-in-a-bottle) with a positive phase 2 in Sjogren’s. This study is in high systemic dx pts (with nice response matching biological plausibility) - but salivary flow improved too ESSPRI didn’t quite make it, but close #EULAR2024 LBA0010 @RheumNow https://t.co/PslFKJBOOr